X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (52) 52
humans (51) 51
female (41) 41
middle aged (40) 40
male (37) 37
adult (33) 33
hematology (32) 32
aged (28) 28
oncology (20) 20
adolescent (16) 16
therapy (13) 13
transplantation (13) 13
retrospective studies (12) 12
treatment outcome (12) 12
prognosis (10) 10
risk factors (10) 10
survival (10) 10
young adult (10) 10
chemotherapy (9) 9
stem cells (9) 9
abridged index medicus (8) 8
bone-marrow-transplantation (8) 8
cancer (8) 8
classification (8) 8
hematopoietic stem cell transplantation (8) 8
lymphomas (8) 8
recurrence (8) 8
acute myeloid-leukemia (7) 7
hepatitis c (7) 7
analysis (6) 6
cyclophosphamide (6) 6
disease (6) 6
follow-up studies (6) 6
immunology (6) 6
italy - epidemiology (6) 6
patients (6) 6
risk (6) 6
stem cell transplantation (6) 6
survival analysis (6) 6
aged, 80 and over (5) 5
care and treatment (5) 5
child (5) 5
gastroenterology & hepatology (5) 5
guidelines (5) 5
hematology, oncology and palliative medicine (5) 5
hematopoietic stem cells (5) 5
hepatitis (5) 5
hepatitis c virus (5) 5
imatinib mesylate (5) 5
infection (5) 5
leukemia (5) 5
lymphocytes (5) 5
lymphoma (5) 5
medicine & public health (5) 5
recombinant proteins (5) 5
research (5) 5
transplants & implants (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
benzamides (4) 4
blood (4) 4
bone marrow (4) 4
combined modality therapy (4) 4
disease-free survival (4) 4
epidemiology (4) 4
genotype (4) 4
health aspects (4) 4
hematopoietic stem cell mobilization - methods (4) 4
hepacivirus - genetics (4) 4
hepatitis c - complications (4) 4
hepatitis c, chronic - drug therapy (4) 4
infectious diseases (4) 4
original (4) 4
predictive value of tests (4) 4
prospective studies (4) 4
survival rate (4) 4
time factors (4) 4
toxicity (4) 4
transplantation, homologous (4) 4
acute myeloid leukemia (3) 3
allografts (3) 3
antineoplastic agents - therapeutic use (3) 3
antiviral agents - therapeutic use (3) 3
chronic lymphocytic-leukemia (3) 3
cohort studies (3) 3
cryoglobulinemia (3) 3
cyclophosphamide - administration & dosage (3) 3
cyclophosphamide - therapeutic use (3) 3
development and progression (3) 3
diagnosis (3) 3
drug therapy, combination (3) 3
fludarabine (3) 3
graft-versus-host reaction (3) 3
hand transplantation (3) 3
hematopoiesis (3) 3
hematopoietic stem cell transplantation - methods (3) 3
hepatitis-c virus (3) 3
hepatocellular-carcinoma (3) 3
incidence (3) 3
infections (3) 3
interferon (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BioMed Research International, ISSN 2314-6133, 2014, Volume 2014, pp. 710642 - 8
Journal Article
Blood, ISSN 0006-4971, 10/2012, Volume 120, Issue 16, pp. 3222 - 3228
Journal Article
Haematologica, ISSN 0390-6078, 03/2010, Volume 95, Issue 3, pp. 476 - 484
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2015, Volume 10, Issue 2, pp. e0117420 - e0117420
Background The variability in the association of host innate immune response to Hepatitis C virus (HCV) infection requires ruling out the possible role of host... 
NATURAL-KILLER-CELLS | HEPATOCELLULAR-CARCINOMA | MURINE LIVER | LIVER-TRANSPLANTATION | INCREASED RISK | MULTIDISCIPLINARY SCIENCES | HEPATOMA-CELLS | MIXED CRYOGLOBULINEMIA | HCV INFECTION | T-CELLS | RECEPTOR GENES | Genetic Predisposition to Disease | Receptors, KIR - genetics | Receptors, KIR2DL5 - genetics | Gene Frequency | Humans | Middle Aged | Genotype | Hepatitis C - genetics | Male | Genetic Loci | HLA Antigens - genetics | Linkage Disequilibrium | Centromere - genetics | Adult | Female | Hepacivirus - physiology | Hepatitis C - complications | Aged | Hepatitis C - pathology | Telomere - genetics | Infection | Development and progression | Lymphomas | Disease susceptibility | Hepatitis C virus | Health aspects | Biological diversity | Hepatitis B | KIR protein | Therapy | Disease | Liver | Disorders | Chronic infection | Cytotoxicity | Epidemiology | Hepatitis | α-Interferon | Human immunodeficiency virus--HIV | Killer cell immunoglobulin-like receptors | Antigens | Immunoglobulins | Liver diseases | T cell receptors | Patients | Molecular chains | Diseases | Hospitals | Genotyping | Ligands | KIR2DS3 gene | Tissue typing | Transplants & implants | Toxicity | Genes | Linkage disequilibrium | Risk | Viruses | Oncology | Infections | Lymphocytes | Genotypes | Immune system | Cryoglobulinemia | Immune response | Potassium channels (inwardly-rectifying) | Immunoproliferative diseases | Data processing | Genetic diversity | Lymphoma | Immune systems | Interferon | Histocompatibility antigen HLA | Hepatitis C | Molecular biology | Viral infections | Cancer | Index Medicus | Human immunodeficiency virus | HIV
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2003, Volume 9, Issue 2, pp. 625 - 632
Purpose: Imatinib (Glivec) is a potent inhibitor of bcr/abl, an oncogenic fusion protein that causes chronic myelogenous leukemia (CML). α1 acid glycoprotein... 
Journal Article
American Journal of Hematology, ISSN 0361-8609, 10/2018, Volume 93, Issue 10, pp. 1211 - 1219
Busulfan plus cyclophosphamide (BuCy) is the traditional conditioning regimen for allogeneic stem cell transplant (allo‐SCT) for young, fit patients with acute... 
TOTAL-BODY IRRADIATION | REDUCED-INTENSITY | PREPARATIVE REGIMEN | PLUS CYCLOPHOSPHAMIDE | EUROPEAN-GROUP | BONE-MARROW-TRANSPLANTATION | 1ST REMISSION | RANDOMIZED-TRIAL | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | WORKING PARTY | Myeloablative Agonists - therapeutic use | Thiotepa - therapeutic use | Confidence Intervals | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Humans | Middle Aged | Drug Evaluation | Male | Living Donors | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Allografts | Bone Marrow Transplantation | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Transplantation Conditioning - adverse effects | Retrospective Studies | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Siblings | Busulfan - adverse effects | Busulfan - therapeutic use | Vidarabine - adverse effects | Proportional Hazards Models | Combined Modality Therapy | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Myeloablative Agonists - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Thiotepa - adverse effects | Cyclophosphamide | Transplantation | Comparative analysis | Thiotepa | Stem cells | Fludarabine | Cord blood | Donors | Transplants & implants | Myeloid leukemia | Leukemia | Remission | Busulfan | Acute myeloid leukemia | Index Medicus
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 04/2018, Volume 53, Issue 4, pp. 461 - 473
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 04/2018, Volume 53, Issue 4, pp. 422 - 430
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2018, Volume 93, Issue 1, pp. 31 - 39
Journal Article
Journal Article
Blood, ISSN 0006-4971, 04/2014, Volume 123, Issue 15, pp. 2333 - 2342
Journal Article